Plavix sNDA priority review
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb/Sanofi-Aventis' Plavix (clopidogrel) sNDA seeking a claim for treatment of acute ST-segment elevation myocardial infarction (STEMI) has a May 17 PDUFA goal date after being granted priority review status. The sponsors say data from ongoing clinical trials of Plavix in the STEMI setting will be presented at the American College of Cardiology annual meeting in March. The priority designation comes as BMS and Sanofi face patent challenges for the antithrombotic from generic firm Apotex. While BMS believes Plavix' patent expires in 2011, FDA granted final approval to Apotex' generic clopidogrel Jan. 20. "We are vigorously pursuing the pending patent litigation," Bristol CEO Peter Dolan said Jan. 25 during the firm's year-end earnings presentation...
You may also be interested in...
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
US FDA Commissioner Race Shrinks And Widens: Biden Team Trying To Woo Reluctant Dems On Woodcock While Exploring New Options
White House is trying to overcome some Senate Democrats’ opposition to Janet Woodcock as FDA Commissioner, while also looking for other candidates for the job. Josh Sharfstein, long thought to be Woodcock’s main competition, is not a strong contender.